Glasdegib Maleate – Uses, Dosage, Side Effects, Interaction Glasdegib is an orally available small molecule inhibitor of the signaling molecule hedgehog which is used as an antineoplastic agent in the treatment of acute myeloid leukemia. Glasdegib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury. Glasdegib is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methyl piperidine-2-yl group at position 2. It is a hedgehog signaling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy. It has a role as an SMO receptor antagonist, a Hedgehog signaling pathway inhibitor, and an antineoplastic agent. It is a member of benzimidazoles, a member of piperidines, a member of phenyl ureas, and a nitrile. Glasdegib is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation, and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies. Glasdegib Maleate is the maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets bind to and inhibit the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers. Mechanism of Action Glasdegib is a potent and selective inhibitor of the hedgehog signaling pathway that acts by binding to the smoothened (SMO) receptor. The hedgehog signaling pathway is involved in the maintenance of neural and skin stem cells. In this pathway, the binding of specific ligands to the transmembrane receptor patched (PTCH1) allows the activation of the transcriptional regulators GL11, and GL12, and modulation of the gene expression through SMO-mediated signaling. The aberrant activation of the hedgehog pathway is thought to be implicated in the pathogenesis of chronic myeloid leukemia, medulloblastoma, and basal cell carcinoma due to the hyperproliferative state that a modification of this pathway will produce. In preclinical studies, glasdegib achieved a significant reduction in leukemic stem cell burden in xenograft models and a reduction in the cell population expressing leukemic stem cell markers. In clinical trials, glasdegib demonstrated a marked downregulation of more than 80% of the expression of glioma-associated transcriptional regulator GL11 in the skin. In this same study, 8% of the studied individuals with acute myeloid leukemia achieved morphological complete remission while 31% achieved a stable disease state. The latest clinical trial proved glasdegib to generate an overall survival of 8.3 months which was almost double what has been observed in patients under low-dose cytarabine treatment. As well, there have been reports of dose-dependent QTc prolongation in patients administered with glasdegib. Indications Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy. Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of the blood and bone marrow and it is the most common type of acute leukemia in adults. Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in adult patients who are not candidates for standard induction chemotherapy. Glasdegib is an orally available small molecule inhibitor of the signaling molecule hedgehog which is used as an antineoplastic agent in the treatment of acute myeloid leukemia. Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy. Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of the blood and bone marrow and it is the most common type of acute leukemia in adults.[rx] Acute Myeloid Leukemia (AML) Use in Cancer Glasdegib maleate is approved to treat: Acute myeloid leukemia that is newly diagnosed. It is used with low-dose cytarabine in patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy. Glasdegib maleate is also being studied in the treatment of other types of cancer. Contraindications are allergic to glasdegib or any ingredients of the medication are male and are unwilling or unable to use effective birth control are female, may become pregnant, and are unwilling or unable to use effective birth control are pregnant are breast-feeding Anemia Decreased Blood Platelets Low Levels Of A Type Of White Blood Cell Called Neutrophils Bleeding Stomatitis, A Condition With Painful Swelling And Sores Inside The Mouth Constipation Low Energy Taste Impairment A Skin Rash Visible Water Retention Decreased Appetite Nause Pain In The Muscles Or Bone Low Amount Of Phosphate In The Blood Low Amount Of Sodium In The Blood High Levels Of Potassium In The Blood Low Amount Of Potassium In The Blood Atrial Fibrillation Slow Heartbeat Sinus Tachycardia, A Type Of Fast Heart Rate Prolonged QT Interval On EKG Pneumonia Decreased Kidney Function High Amount Of Bilirubin In The Blood Atrial Arrhythmia, A Type Or Abnormal Heart Beat A Tooth Disease A Toothache Hair Loss Muscle Spasm Dizziness Fever Weight Loss Headache Cough Vomiting Diarrhea Intense Abdominal Pain A Heart Attack Rapid Ventricular Heartbeat Ventricular Fibrillation, A Heart Rhythm Disorder Ventricular Arrhythmias, A Type Of Abnormal Heart Rhythm Dosage Strengths: 25 mg; 100 mg Acute Myeloid Leukemia 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response This drug, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude the use of intensive induction chemotherapy Acute Myeloid Leukemia 75 years or older: 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response This drug, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude use of intensive induction chemotherapy Dose Adjustments Dose Modifications for Adverse Reactions: QTC INTERVAL PROLONGATION ON AT LEAST 2 SEPARATE ELECTROCARDIOGRAMS (ECGS): QTc interval greater than 480 ms to 500 ms: Assess electrolyte levels as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation to less than or equal to 480 ms. QTc interval greater than 500 ms: Assess electrolyte levels and supplement as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; interrupt therapy; resume therapy at a reduced dose of 50 mg once daily when QTc interval returns to within 30 ms of baseline or less than or equal to 480 ms; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation; consider re-escalating the dose to 100 mg daily if an alternative etiology for the QTc prolongation can be identified. QTc interval prolongation with life-threatening arrhythmia: Permanently discontinue therapy. HEMATOLOGIC TOXICITY: Platelets less than 10 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently. Neutrophil count less than 0.5 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently. NONHEMATOLOGIC TOXICITY: Grade 3: Interrupt this drug and/or low-dose cytarabine until symptoms reduce to mild or return to baseline; resume this drug at the same dose level, or at a reduced dose of 50 mg; resume low-dose cytarabine at the same dose level, or at a reduced dose of 10 or 15 mg; if toxicity recurs, discontinue this drug and low-dose cytarabine; if toxicity is attributable to this drug only, low-dose cytarabine may be continued. Grade 4: Discontinue this drug and low-dose cytarabine permanently. DOSE MODIFICATION FOR CONCOMITANT USE WITH MODERATE CYP450 3A4 INDUCERS: Avoid concomitant use of this drug with moderate CYP450 3A4 inducers. If concomitant use cannot be avoided, increase the dose of this drug as tolerated as shown below: After the moderate CYP450 3A4 inducer has been discontinued for 7 days, resume this drug at the dose taken prior to initiating the moderate CYP450 3A4 inducer. DOSE MODIFICATION OF THIS DRUG WHEN TAKEN WITH MODERATE CYP450 INDUCERS: If the current dose is 100 mg once a day: Increase it to 200 mg orally once a day. If the current dose is 50 mg orally once a day: Increase it to 100 mg orally once a day. Administration advice: This drug may be taken with or without food. Do not split, divide, or crush tablets. Administer at the same time each day. If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours. Side Effects The Most Common Black, tarry stools bleeding gums blood in the urine or stools chest pain chills confusion cough coughing up blood decreased frequency or amount of urine difficult or labored breathing difficulty in swallowing dizziness or fainting drowsiness dry mouth fainting fast, slow, or irregular heartbeat fever headache increased blood pressure increased menstrual flow or vaginal bleeding increased thirst lightheadedness loss of appetite loss of consciousness lower back or side pain mood or mental changes muscle pain or cramps muscle spasms (tetany) or twitching seizures nausea nervousness nosebleeds numbness or tingling in the hands, feet, or lips painful or difficult urination pale skin paralysis pinpoint red spots on the skin pounding heartbeat prolonged bleeding from cuts rapid, shallow breathing red or black, tarry stools red or dark brown urine seizures sneezing sore throat stomach pain swelling of the face, hands, ankles, or lower legs tightness in the chest trembling troubled breathing with exertion ulcers, sores, or white spots in the mouth unusual bleeding or bruising unusual tiredness or weakness vomiting weakness or heaviness of the legs weight gain More common Bone or muscle pain change in taste constipation cracked lips decreased appetite diarrhea loose tooth loss of taste skin rash thinning or loss of hair toothache changes in sense of taste decreased appetite fatigue hair loss headache muscle, joint, or bone pain muscle spasms or tightness nausea rash sores or pain in the mouth or throat Rare stomach pain toothache or loose tooth weakness weight loss irregular heartbeat (e.g., fast, slow, or pounding heartbeat; shortness of breath; dizziness) signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding) signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain) swelling arms, legs, face symptoms of low sodium levels in the blood (e.g., achy, stiff, or uncoordinated muscles; confusion; tiredness; weakness) symptoms of pneumonia (e.g., fever or chills, shortness of breath, fatigue, chest pain, cough) eye bleeding (e.g., blurred vision, pain when exposed to light, eye bruising) severe breathing problems (respiratory failure: blue color to skin, lips, or fingernails; sleepiness; irregular heartbeat; shortness of breath; loss of consciousness) signs of bleeding in the stomach (e.g., bloody, black, or tarry stools; spitting up of blood; vomiting blood or material that looks like coffee grounds) signs of bleeding in the brain (e.g., sudden or severe headache; sudden loss of coordination; vision changes; sudden slurring of speech; or unexplained weakness, numbness, or pain in arm or leg) signs of a heart attack (e.g., sudden chest pain or pain radiating to back, down arm, jaw; sensation of fullness of the chest; nausea; vomiting; sweating; anxiety) Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Glasdegib can be increased when it is combined with Abametapir. Abatacept The metabolism of Glasdegib can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Glasdegib. Abiraterone The metabolism of Glasdegib can be decreased when combined with Abiraterone. Abrocitinib The serum concentration of Glasdegib can be increased when it is combined with Abrocitinib. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Glasdegib. Acyclovir The excretion of Acyclovir can be decreased when combined with Glasdegib. Adalimumab The metabolism of Glasdegib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Glasdegib. Afatinib The serum concentration of Afatinib can be increased when it is combined with Glasdegib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Glasdegib. Alectinib Alectinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Glasdegib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Glasdegib. Allopurinol Glasdegib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The metabolism of Glasdegib can be decreased when combined with Almotriptan. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Glasdegib. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Glasdegib. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Glasdegib. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Glasdegib. Aminophenazone The metabolism of Glasdegib can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Glasdegib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Glasdegib. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Glasdegib. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Glasdegib. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Glasdegib. Amprenavir The metabolism of Glasdegib can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Glasdegib. Anakinra The metabolism of Glasdegib can be increased when combined with Anakinra. Anastrozole The metabolism of Glasdegib can be decreased when combined with Anastrozole. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Glasdegib. Antipyrine The metabolism of Glasdegib can be decreased when combined with Antipyrine. Apalutamide The serum concentration of Glasdegib can be decreased when it is combined with Apalutamide. Apixaban Glasdegib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Glasdegib. Apremilast The metabolism of Glasdegib can be increased when combined with Apremilast. Aprepitant The metabolism of Glasdegib can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Glasdegib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Glasdegib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Glasdegib. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Glasdegib. Artemether The risk or severity of QTc prolongation can be increased when Artemether is combined with Glasdegib. Articaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Articaine. Asciminib The serum concentration of Glasdegib can be increased when it is combined with Asciminib. Asenapine The risk or severity of QTc prolongation can be increased when Asenapine is combined with Glasdegib. Astemizole The risk or severity of QTc prolongation can be increased when Astemizole is combined with Glasdegib. Asunaprevir The serum concentration of Glasdegib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Glasdegib can be decreased when combined with Atazanavir. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Glasdegib. Atorvastatin The metabolism of Glasdegib can be decreased when combined with Atorvastatin. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Glasdegib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Glasdegib. Avatrombopag Avatrombopag may decrease the excretion rate of Glasdegib which could result in a higher serum level. Axitinib The serum concentration of Axitinib can be increased when it is combined with Glasdegib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Glasdegib. Azelastine The metabolism of Glasdegib can be decreased when combined with Azelastine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Glasdegib. Baricitinib The excretion of Baricitinib can be decreased when combined with Glasdegib. Beclomethasone Beclomethasone dipropionate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Glasdegib. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib. Belinostat The serum concentration of Belinostat can be increased when it is combined with Glasdegib. Belumosudil Belumosudil may decrease the excretion rate of Glasdegib which could result in a higher serum level. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Glasdegib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Glasdegib. Benzocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Bepridil is combined with Glasdegib. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Glasdegib. Betamethasone The metabolism of Glasdegib can be increased when combined with Betamethasone. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Glasdegib. Bexarotene The metabolism of Glasdegib can be decreased when combined with Bexarotene. Bezafibrate The metabolism of Glasdegib can be decreased when combined with Bezafibrate. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Glasdegib. Bimekizumab The metabolism of Glasdegib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Glasdegib. Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Glasdegib. Boceprevir The metabolism of Glasdegib can be decreased when combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Glasdegib. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Glasdegib. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Glasdegib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Glasdegib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Glasdegib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Glasdegib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Glasdegib which could result in a higher serum level. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Glasdegib. Butacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Glasdegib. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Glasdegib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Glasdegib. Cabozantinib The metabolism of Glasdegib can be decreased when combined with Cabozantinib. Caffeine Caffeine may decrease the excretion rate of Glasdegib which could result in a higher serum level. Canagliflozin The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Glasdegib can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Glasdegib can be decreased when combined with Candesartan cilexetil. Cannabidiol Cannabidiol may decrease the excretion rate of Glasdegib which could result in a higher serum level. Capmatinib The serum concentration of Glasdegib can be increased when it is combined with Capmatinib. You Might Also Read Cabozantinib - Uses, Dosage, Side Effects, Interaction Capsaicin The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Capsaicin. Carbamazepine The metabolism of Glasdegib can be increased when combined with Carbamazepine. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Glasdegib. Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Glasdegib. Carvedilol The serum concentration of Glasdegib can be increased when it is combined with Carvedilol. Cefradine The excretion of Cefradine can be decreased when combined with Glasdegib. Celecoxib Glasdegib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Glasdegib. Cenobamate The serum concentration of Glasdegib can be decreased when it is combined with Cenobamate. Cephalexin The excretion of Cephalexin can be decreased when combined with Glasdegib. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Glasdegib. Cerivastatin Glasdegib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. Certolizumab The metabolism of Glasdegib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Glasdegib. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Glasdegib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Glasdegib. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Glasdegib. Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Glasdegib. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Glasdegib. Cholesterol Cholesterol may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Glasdegib. Cimetidine The metabolism of Glasdegib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Glasdegib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Glasdegib. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Glasdegib. Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Glasdegib. Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Glasdegib. Cladribine Glasdegib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Glasdegib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Glasdegib. Clobazam The serum concentration of Clobazam can be increased when it is combined with Glasdegib. Clofarabine Glasdegib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Glasdegib. Clomifene The serum concentration of Clomifene can be increased when it is combined with Glasdegib. Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Glasdegib. Clopidogrel The metabolism of Glasdegib can be decreased when combined with Clopidogrel. Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Glasdegib. Cobicistat The metabolism of Glasdegib can be decreased when combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Glasdegib. Cocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cocaine. Colchicine The serum concentration of Colchicine can be increased when it is combined with Glasdegib. Conivaptan The metabolism of Glasdegib can be decreased when combined with Conivaptan. Conjugated estr Glasdegib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Glasdegib. Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Glasdegib. Curcumin The metabolism of Glasdegib can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Glasdegib. Cyclophosphamide The metabolism of Glasdegib can be increased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Glasdegib. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Glasdegib. Dabrafenib The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib. Daclatasvir Daclatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Glasdegib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Glasdegib. Danazol The metabolism of Glasdegib can be decreased when combined with Danazol. Dapsone The metabolism of Glasdegib can be decreased when combined with Dapsone. Daptomycin The serum concentration of Daptomycin can be increased when it is combined with Glasdegib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glasdegib. Darolutamide The serum concentration of Glasdegib can be increased when it is combined with Darolutamide. Darunavir The metabolism of Glasdegib can be decreased when combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Glasdegib. Daunorubicin Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Deferasirox The metabolism of Glasdegib can be decreased when combined with Deferasirox. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Glasdegib. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Glasdegib. Delamanid Glasdegib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Glasdegib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Glasdegib. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Glasdegib. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Glasdegib. Desvenlafaxine The metabolism of Glasdegib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Deutetrabenazine. Dexamethasone The metabolism of Glasdegib can be increased when combined with Dexamethasone. Dexamethasone Dexamethasone acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Glasdegib. Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Glasdegib. Dexibuprofen The metabolism of Glasdegib can be decreased when combined with Dexibuprofen. Diclofenac The metabolism of Glasdegib can be decreased when combined with Diclofenac. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Glasdegib which could result in a higher serum level. Diflunisal The metabolism of Glasdegib can be decreased when combined with Diflunisal. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Glasdegib. Digoxin Glasdegib may decrease the excretion rate of Digoxin which could result in a higher serum level. Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Glasdegib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Glasdegib. Diosmin The serum concentration of Glasdegib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Glasdegib. Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Glasdegib. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Glasdegib. Dolutegravir Glasdegib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The risk or severity of QTc prolongation can be increased when Domperidone is combined with Glasdegib. Donepezil Glasdegib may decrease the excretion rate of Donepezil which could result in a higher serum level. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Glasdegib. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Glasdegib. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Glasdegib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Glasdegib. Dronedarone Glasdegib may increase the QTc-prolonging activities of Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Glasdegib. Duvelisib Glasdegib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Glasdegib. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Glasdegib. Efavirenz The metabolism of Glasdegib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Elagolix can be increased when it is combined with Glasdegib. Elbasvir Elbasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Eliglustat The serum concentration of Glasdegib can be increased when it is combined with Eliglustat. Eltrombopag The metabolism of Glasdegib can be decreased when combined with Eltrombopag. Elvitegravir The metabolism of Glasdegib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Glasdegib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Glasdegib. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Glasdegib. Enasidenib The metabolism of Enasidenib can be decreased when combined with Glasdegib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Glasdegib. Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Glasdegib. Entrectinib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib. Enzalutamide The serum concentration of Glasdegib can be decreased when it is combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Glasdegib. Erdafitinib The serum concentration of Glasdegib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Glasdegib can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Glasdegib. Erlotinib The metabolism of Erlotinib can be decreased when combined with Glasdegib. Ertugliflozin Glasdegib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Glasdegib. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Glasdegib. Escitalopram The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Glasdegib. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Glasdegib. Estradiol Estradiol may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Glasdegib which could result in a higher serum level. Estrone sulfate The excretion of Estrone sulfate can be decreased when combined with Glasdegib. Eszopiclone The metabolism of Glasdegib can be decreased when combined with Eszopiclone. Etanercept The metabolism of Glasdegib can be increased when combined with Etanercept. Ethinylestradiol The metabolism of Glasdegib can be decreased when combined with Ethinylestradiol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Glasdegib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Etidocaine. Etoposide The serum concentration of Etoposide can be increased when it is combined with Glasdegib. Everolimus The serum concentration of Everolimus can be increased when it is combined with Glasdegib. Ezetimibe Glasdegib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Glasdegib. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Glasdegib. Favipiravir The serum concentration of Glasdegib can be increased when it is combined with Favipiravir. Febuxostat The excretion of Glasdegib can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Glasdegib. Felodipine The metabolism of Glasdegib can be decreased when combined with Felodipine. Fenofibrate The metabolism of Glasdegib can be decreased when combined with Fenofibrate. Fexinidazole The risk or severity of adverse effects can be increased when Glasdegib is combined with Fexinidazole. Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Glasdegib. Finerenone The metabolism of Finerenone can be decreased when combined with Glasdegib. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Glasdegib. Flibanserin The serum concentration of Glasdegib can be increased when it is combined with Flibanserin. Fluconazole The metabolism of Glasdegib can be decreased when combined with Fluconazole. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Glasdegib. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Glasdegib. Flupentixol The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Flupentixol. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Glasdegib. Fluticasone The metabolism of Glasdegib can be decreased when combined with Fluticasone. Fluticasone furoate The metabolism of Glasdegib can be decreased when combined with Fluticasone furoate. Fluticasone propio The metabolism of Glasdegib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Glasdegib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Glasdegib can be decreased when combined with Fluvoxamine. Folic acid Glasdegib may decrease the excretion rate of Folic acid which could result in a higher serum level. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Glasdegib. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Glasdegib. Fosnetupitant The metabolism of Glasdegib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Glasdegib. Fostamatinib Fostamatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Glasdegib. Fusidic acid The metabolism of Glasdegib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Glasdegib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Glasdegib. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Glasdegib. Ganciclovir The excretion of Ganciclovir can be decreased when combined with Glasdegib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Glasdegib. Gefitinib Gefitinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Glasdegib. Gemfibrozil The metabolism of Glasdegib can be decreased when combined with Gemfibrozil. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Glasdegib. Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Glasdegib. Glecaprevir Glasdegib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glyburide Glasdegib may decrease the excretion rate of Glyburide which could result in a higher serum level. Golimumab The metabolism of Glasdegib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Glasdegib. Grazoprevir Grazoprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Glasdegib. Guanidine The excretion of Guanidine can be decreased when combined with Glasdegib. Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Glasdegib. Haloperidol The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Glasdegib. Hydrochlorothiaz The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Glasdegib. Hydrocortisone The metabolism of Glasdegib can be increased when combined with Hydrocortisone. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Glasdegib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Glasdegib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Glasdegib. Ibuprofen The metabolism of Glasdegib can be decreased when combined with Ibuprofen. Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Glasdegib. Idelalisib Glasdegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Ifosfamide The metabolism of Glasdegib can be increased when combined with Ifosfamide. Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Glasdegib. Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Glasdegib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Glasdegib. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Glasdegib. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Glasdegib. Indinavir The metabolism of Glasdegib can be decreased when combined with Indinavir. Infliximab The metabolism of Glasdegib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Glasdegib. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glasdegib. Irbesartan The metabolism of Glasdegib can be decreased when combined with Irbesartan. Irinotecan Glasdegib may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The serum concentration of Glasdegib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Glasdegib can be increased when it is combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Glasdegib. Isoniazid The metabolism of Glasdegib can be decreased when combined with Isoniazid. Isradipine The metabolism of Glasdegib can be decreased when combined with Isradipine. Istradefylline Istradefylline may decrease the excretion rate of Glasdegib which could result in a higher serum level. Itraconazole The metabolism of Glasdegib can be decreased when combined with Itraconazole. Ivabradine The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Glasdegib. Ivacaftor The serum concentration of Glasdegib can be increased when it is combined with Ivacaftor. Ivermectin Glasdegib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ivosidenib. Ixabepilone The serum concentration of Glasdegib can be increased when it is combined with Ixabepilone. Ketamine The metabolism of Glasdegib can be decreased when combined with Ketamine. Ketoconazole The metabolism of Glasdegib can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Glasdegib can be decreased when combined with Ketoprofen. Ketorolac The metabolism of Glasdegib can be decreased when combined with Ketorolac. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Glasdegib. Lamivudine Glasdegib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Glasdegib. Lansoprazole Lansoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Glasdegib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Glasdegib. Lasmiditan The serum concentration of Glasdegib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Glasdegib. Lefamulin Lefamulin may increase the QTc-prolonging activities of Glasdegib. Leflunomide Glasdegib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Glasdegib. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Glasdegib. Letermovir Letermovir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Glasdegib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Glasdegib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Glasdegib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Glasdegib. Levoketoconazole The metabolism of Glasdegib can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Glasdegib. Levomilnacipran The metabolism of Glasdegib can be decreased when combined with Levomilnacipran. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Glasdegib. Levothyroxine The metabolism of Glasdegib can be decreased when combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Glasdegib. Linagliptin The metabolism of Glasdegib can be decreased when combined with Linagliptin. Linzagolix The serum concentration of Glasdegib can be increased when it is combined with Linzagolix. Liotrix The metabolism of Glasdegib can be decreased when combined with Liotrix. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Glasdegib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Glasdegib. Lomitapide The serum concentration of Glasdegib can be increased when it is combined with Lomitapide. Lonafarnib The metabolism of Glasdegib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Glasdegib. Loperamide The excretion of Loperamide can be decreased when combined with Glasdegib. Lopinavir The metabolism of Glasdegib can be decreased when combined with Lopinavir. Loratadine The metabolism of Glasdegib can be decreased when combined with Loratadine. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Glasdegib. Lovastatin The metabolism of Glasdegib can be decreased when combined with Lovastatin. Loxapine The serum concentration of Glasdegib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Glasdegib can be decreased when it is combined with Lumacaftor. Lumefantrine The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Glasdegib. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Glasdegib. Lusutrombopag Glasdegib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Macimorelin The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Macimorelin. Mannitol The serum concentration of Mannitol can be increased when it is combined with Glasdegib. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Glasdegib. Maribavir Maribavir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Mavacamten The serum concentration of Glasdegib can be decreased when it is combined with Mavacamten. Medroxyprogest The metabolism of Glasdegib can be decreased when combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Glasdegib can be decreased when combined with Mefenamic acid. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Glasdegib. Meloxicam The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Meloxicam. Mephenytoin The metabolism of Glasdegib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Mepivacaine. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Glasdegib. Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Glasdegib. Mestranol The metabolism of Glasdegib can be decreased when combined with Mestranol. Metformin The excretion of Metformin can be decreased when combined with Glasdegib. Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Glasdegib. Methimazole The metabolism of Glasdegib can be decreased when combined with Methimazole. Methotrexate Glasdegib may decrease the excretion rate of Methotrexate which could result in a higher serum level. You Might Also Read Ulipristal Side Effects - Indication, Contraindications Methotrimepra The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Glasdegib. Methoxy polyeth The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glasdegib. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Glasdegib. Methylene blue The serum concentration of Glasdegib can be increased when it is combined with Methylene blue. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Glasdegib. Metreleptin The metabolism of Glasdegib can be increased when combined with Metreleptin. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Glasdegib. Miconazole The metabolism of Glasdegib can be decreased when combined with Miconazole. Midostaurin The metabolism of Glasdegib can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Glasdegib can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Glasdegib can be decreased when combined with Milnacipran. Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Glasdegib. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Glasdegib. Mitapivat The serum concentration of Glasdegib can be increased when it is combined with Mitapivat. Mitotane The metabolism of Glasdegib can be increased when combined with Mitotane. Mitoxantrone Glasdegib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Glasdegib. Mobocertinib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Mobocertinib. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Glasdegib. Mometasone furoate The metabolism of Glasdegib can be decreased when combined with Mometasone furoate. Montelukast The metabolism of Glasdegib can be decreased when combined with Montelukast. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Glasdegib. Morphine The serum concentration of Morphine can be increased when it is combined with Glasdegib. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Glasdegib. Mycophenolate Glasdegib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nadolol The excretion of Nadolol can be decreased when combined with Glasdegib. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Glasdegib. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Glasdegib. Naloxone The metabolism of Glasdegib can be decreased when combined with Naloxone. Naproxen The metabolism of Glasdegib can be decreased when combined with Naproxen. Nefazodone The metabolism of Glasdegib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Glasdegib can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Glasdegib can be increased when it is combined with Neratinib. Netupitant The metabolism of Glasdegib can be decreased when combined with Netupitant. Nicardipine The metabolism of Glasdegib can be decreased when combined with Nicardipine. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Glasdegib. Nilotinib The metabolism of Glasdegib can be decreased when combined with Nilotinib. Nilutamide The metabolism of Glasdegib can be decreased when combined with Nilutamide. Nilvadipine The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Glasdegib. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Glasdegib. Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Glasdegib. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Glasdegib. Nitrofurantoin Glasdegib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Glasdegib. Norgestimate The serum concentration of Glasdegib can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Glasdegib. Novobiocin Novobiocin may decrease the excretion rate of Glasdegib which could result in a higher serum level. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Glasdegib. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Glasdegib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Glasdegib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Glasdegib. Ombitasvir Glasdegib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole Omeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Glasdegib. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Glasdegib. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Glasdegib. Oteseconazole The serum concentration of Glasdegib can be increased when it is combined with Oteseconazole. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib. Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Glasdegib. Oxetacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxybuprocaine. Oxybutynin The metabolism of Glasdegib can be decreased when combined with Oxybutynin. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib. Ozanimod Glasdegib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Glasdegib. Pacritinib The serum concentration of Glasdegib can be increased when it is combined with Pacritinib. Palbociclib Palbociclib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Paliperidone The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Glasdegib. Pantoprazole Pantoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib. Paramethadione The metabolism of Glasdegib can be decreased when combined with Paramethadione. Paritaprevir Paritaprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Glasdegib. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Glasdegib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Glasdegib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Glasdegib. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Glasdegib. Pentobarbital The metabolism of Glasdegib can be increased when combined with Pentobarbital. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Glasdegib. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Glasdegib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Glasdegib. Phenobarbital The metabolism of Glasdegib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Glasdegib. Phenytoin The metabolism of Phenytoin can be decreased when combined with Glasdegib. Pibrentasvir Glasdegib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimozide The risk or severity of QTc prolongation can be increased when Pimozide is combined with Glasdegib. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Glasdegib. Pioglitazone The metabolism of Glasdegib can be decreased when combined with Pioglitazone. Piroxicam The metabolism of Glasdegib can be decreased when combined with Piroxicam. Pitavastatin Glasdegib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Glasdegib can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Glasdegib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Glasdegib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Glasdegib. Posaconazole The metabolism of Glasdegib can be decreased when combined with Posaconazole. Pralatrexate Glasdegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Glasdegib. Pramocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Glasdegib which could result in a higher serum level. Prazosin Glasdegib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The serum concentration of Prednisolone phosphate can be increased when it is combined with Glasdegib. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Glasdegib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Glasdegib. Prilocaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Glasdegib. Primidone The metabolism of Glasdegib can be increased when combined with Primidone. Probenecid The metabolism of Glasdegib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Glasdegib. Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Glasdegib. Procaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Glasdegib. Progesterone Progesterone may decrease the excretion rate of Glasdegib which could result in a higher serum level. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Glasdegib. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Glasdegib. Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Glasdegib. Proparacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Glasdegib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Propoxycaine. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Glasdegib. Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Glasdegib. Pyrimethamine The metabolism of Glasdegib can be decreased when combined with Pyrimethamine. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Glasdegib. Quinidine The serum concentration of Quinidine can be increased when it is combined with Glasdegib. Quinine The risk or severity of QTc prolongation can be increased when Quinine is combined with Glasdegib. Rabeprazole Rabeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. Raloxifene Glasdegib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Glasdegib. Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Glasdegib. Relebactam The excretion of Relebactam can be decreased when combined with Glasdegib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Glasdegib. Repaglinide The metabolism of Glasdegib can be decreased when combined with Repaglinide. Reserpine The serum concentration of Glasdegib can be increased when it is combined with Reserpine. Revefenacin Glasdegib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Glasdegib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Glasdegib can be increased when combined with Rifabutin. Rifampicin The metabolism of Glasdegib can be increased when combined with Rifampicin. Rifamycin The metabolism of Glasdegib can be increased when combined with Rifamycin. Rifapentine The metabolism of Glasdegib can be increased when combined with Rifapentine. Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Glasdegib. Rilonacept The metabolism of Glasdegib can be increased when combined with Rilonacept. Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Glasdegib. Riluzole Glasdegib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Glasdegib. Riociguat Glasdegib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib Glasdegib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Glasdegib. Ritonavir The serum concentration of Glasdegib can be increased when it is combined with Ritonavir. Rivaroxaban Glasdegib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rofecoxib The metabolism of Glasdegib can be decreased when combined with Rofecoxib. Rolapitant Rolapitant may decrease the excretion rate of Glasdegib which could result in a higher serum level. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Glasdegib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ropivacaine. Rosiglitazone The metabolism of Glasdegib can be decreased when combined with Rosiglitazone. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Glasdegib. Rosuvastatin Glasdegib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Roxadustat The serum concentration of Glasdegib can be increased when it is combined with Roxadustat. Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Glasdegib. Rucaparib Glasdegib may decrease the excretion rate of Rucaparib which could result in a higher serum level. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Glasdegib. Safinamide Safinamide may decrease the excretion rate of Glasdegib which could result in a higher serum level. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Glasdegib. Salmeterol The metabolism of Glasdegib can be decreased when combined with Salmeterol. Sapropterin The serum concentration of Glasdegib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Glasdegib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Glasdegib can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Glasdegib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Glasdegib can be increased when combined with Secobarbital. Secukinumab The metabolism of Glasdegib can be increased when combined with Secukinumab. Selegiline The metabolism of Glasdegib can be decreased when combined with Selegiline. Selexipag The serum concentration of Selexipag can be increased when it is combined with Glasdegib. Selpercatinib The serum concentration of Glasdegib can be increased when it is combined with Selpercatinib. Selumetinib Glasdegib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Glasdegib. Sildenafil The serum concentration of Glasdegib can be increased when it is combined with Sildenafil. Silodosin The excretion of Silodosin can be decreased when combined with Glasdegib. Siltuximab The metabolism of Glasdegib can be increased when combined with Siltuximab. Simeprevir The metabolism of Glasdegib can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Glasdegib can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Glasdegib. Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Glasdegib. Sofosbuvir Glasdegib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Glasdegib. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Glasdegib. Somatrogon The metabolism of Glasdegib can be increased when combined with Somatrogon. Sorafenib The metabolism of Sorafenib can be decreased when combined with Glasdegib. Sotagliflozin Sotagliflozin may decrease the excretion rate of Glasdegib which could result in a higher serum level. Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Glasdegib. Sotorasib The serum concentration of Glasdegib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Glasdegib. Spironolactone The metabolism of Glasdegib can be decreased when combined with Spironolactone. St. John’s Wort The metabolism of Glasdegib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Glasdegib can be decreased when combined with Stiripentol. Sulfadiazine The metabolism of Glasdegib can be decreased when combined with Sulfadiazine. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Glasdegib. Sulfaphenazole The metabolism of Glasdegib can be decreased when combined with Sulfaphenazole. Sulfasalazine Sulfasalazine may decrease the excretion rate of Glasdegib which could result in a higher serum level. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Glasdegib. You Might Also Read Eletriptan; Uses, Dosage, Side Effects, Interactions Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Glasdegib. Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Glasdegib. Sumatriptan Glasdegib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Glasdegib. Suvorexant The serum concentration of Glasdegib can be increased when it is combined with Suvorexant. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Glasdegib. Tafamidis The serum concentration of Glasdegib can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Glasdegib. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Glasdegib. Taurocholic acid Taurocholic acid may decrease the excretion rate of Glasdegib which could result in a higher serum level. Tazarotene The metabolism of Glasdegib can be decreased when combined with Tazarotene. Tazemetostat Glasdegib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Technetium Tc The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glasdegib. Tecovirimat The metabolism of Glasdegib can be increased when combined with Tecovirimat. Tegafur The metabolism of Tegafur can be decreased when combined with Glasdegib. Tegaserod Glasdegib may decrease the excretion rate of Tegaserod which could result in a higher serum level. Telaprevir The metabolism of Glasdegib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Glasdegib. Telithromycin The metabolism of Glasdegib can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Glasdegib which could result in a higher serum level. Telotristat ethyl The serum concentration of Glasdegib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Glasdegib. Teniposide Glasdegib may decrease the excretion rate of Teniposide which could result in a higher serum level. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glasdegib. Tenofovir The serum concentration of Tenofovir disoproxil can be increased when it is combined with Glasdegib. Tepotinib The serum concentration of Tepotinib can be increased when it is combined with Glasdegib. Terbinafine The metabolism of Glasdegib can be decreased when combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Glasdegib. Terfenadine The metabolism of Glasdegib can be decreased when combined with Terfenadine. Teriflunomide The metabolism of Glasdegib can be decreased when combined with Teriflunomide. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Glasdegib. Testosterone Glasdegib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Glasdegib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Glasdegib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Glasdegib. Tetracaine The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Tetracaine. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Glasdegib. Theophylline The metabolism of Glasdegib can be decreased when combined with Theophylline. Thioridazine The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Glasdegib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Glasdegib. Ticagrelor The serum concentration of Glasdegib can be increased when it is combined with Ticagrelor. Ticlopidine The metabolism of Glasdegib can be decreased when combined with Ticlopidine. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Glasdegib. Tipranavir The metabolism of Glasdegib can be decreased when combined with Tipranavir. Tivozanib Tivozanib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Glasdegib. Tocilizumab The metabolism of Glasdegib can be increased when combined with Tocilizumab. Tolbutamide The metabolism of Glasdegib can be decreased when combined with Tolbutamide. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Glasdegib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Glasdegib. Topotecan The serum concentration of Topotecan can be increased when it is combined with Glasdegib. Torasemide The metabolism of Glasdegib can be decreased when combined with Torasemide. Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Glasdegib. Trametinib The metabolism of Glasdegib can be decreased when combined with Trametinib. Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Glasdegib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Glasdegib. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Glasdegib. Tretinoin The metabolism of Glasdegib can be decreased when combined with Tretinoin. Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Glasdegib. Trilaciclib Glasdegib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Glasdegib. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Glasdegib. Trimethoprim The metabolism of Glasdegib can be decreased when combined with Trimethoprim. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Glasdegib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Glasdegib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Glasdegib. Troglitazone The metabolism of Glasdegib can be decreased when combined with Troglitazone. Troleandomycin The metabolism of Glasdegib can be decreased when combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Glasdegib. Tucatinib Tucatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Glasdegib. Umbralisib The serum concentration of Glasdegib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Glasdegib. Valproic acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib. Vandetanib The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Glasdegib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Glasdegib. Velpatasvir Velpatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. Vemurafenib The serum concentration of Glasdegib can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Glasdegib. Venlafaxine Venlafaxine may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The metabolism of Glasdegib can be decreased when combined with Verapamil. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Glasdegib. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Glasdegib. Viloxazine The metabolism of Glasdegib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Glasdegib. Vincristine The excretion of Vincristine can be decreased when combined with Glasdegib. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Glasdegib. Vismodegib Vismodegib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Voclosporin The serum concentration of Glasdegib can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Glasdegib can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Glasdegib can be increased when it is combined with Voriconazole. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Glasdegib. Vortioxetine The metabolism of Glasdegib can be decreased when combined with Vortioxetine. Voxilaprevir Glasdegib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Zidovudine Glasdegib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zimelidine The metabolism of Glasdegib can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ziprasidone. Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Glasdegib. Zopiclone The metabolism of Glasdegib can be decreased when combined with Zopiclone. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Glasdegib. Drug-Food Interactions Avoid St. John’s Wort. This herb induces CYP3A metabolism and may reduce serum levels of glasdegib. Take at the same time every day. Take with or without food. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy This medication should not be used during pregnancy, as it may cause harm to the developing baby. If you become pregnant while taking this medication, contact your doctor immediately. Lactation It is not known if glasdegib passes into breast milk. Breastfeeding is not recommended while taking this medication. The safety and effectiveness of using this medication have not been established for children. Precautions It is very important that your doctor check your progress at regular visits while you are using this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. Blood and urine tests may be needed to check for unwanted effects. Using this medicine while you are pregnant can harm your unborn baby. It may also cause birth defects if the father is using it when his sexual partner becomes pregnant. Female patients should use effective birth control during treatment with this medicine and for at least 30 days after the last dose. Male patients who have female partners should use effective birth control (even after a vasectomy) during treatment with this medicine and for at least 30 days after the last dose. If you think you have become pregnant while using this medicine, tell your doctor right away. Your doctor will give you a pregnancy test within 7 days before you use this medicine to make sure you are not pregnant. Do not donate blood or blood products or sperm while you are using this medicine and for at least 30 days after the last dose. Contact your doctor right away if you have any changes to your heart rhythm. You might feel dizzy or faint, or you might have a fast, pounding, or uneven heartbeat. Make sure your doctor knows if you had a heart rhythm problem, such as QT prolongation. If you plan to have children, talk with your doctor before using this medicine. Some men using this medicine have become infertile (unable to have children). Cancer medicines can cause diarrhea, nausea, vomiting, or stomach pain in most people, sometimes even after receiving medicines to prevent it. Ask your doctor or nurse about other ways to control these unwanted effects. Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements. Before taking this medicine Glasdegib can cause severe birth defects or death of a baby if the mother or the father is taking this medicine at the time of conception or during pregnancy. If you are a woman who is able to get pregnant, you may need to have a negative pregnancy test before starting this treatment. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 30 days after your last dose. If you are a man, use condoms when having sex with a woman who is able to get pregnant, even if you have had a vasectomy. Keep using condoms for at least 30 days after your last dose. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using glasdegib. This medicine may affect fertility (the ability to have children) in men. However, it is important to use birth control to prevent pregnancy because glasdegib can harm an unborn baby. Do not breastfeed while using this medicine, and for at least 30 days after your last dose. References https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210656.pdf https://www.fda.gov/drugs/fda-approves-glasdegib-aml-adults-age-75-or-older-or-who-have-comorbidities https://pubchem.ncbi.nlm.nih.gov/compound/Glasdegib https://pubchem.ncbi.nlm.nih.gov/compound/Glasdegib-maleate https://medlineplus.gov/druginfo/drug_Da.html https://www.drugs.com/mtm/glasdegib.html https://www.mayoclinic.org/drugs-supplements/glasdegib-oral-route/side-effects/drg-20452330?p=1 https://go.drugbank.com/drugs/DB11978 https://en.wikipedia.org/wiki/Glasdegib https://www.webmd.com/drugs/2/drug-176560/glasdegib-oral/details/list-sideeffects ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Glasdegib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/1095173275 https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Glasdegib https://www.drugbank.ca/drugs/DB11978 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Glasdegib https://comptox.epa.gov/dashboard/DTXSID201025881 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea https://echa.europa.eu/information-on-chemicals 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/253537 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking GLASDEGIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/K673DMO5H9 ChEBI Glasdegib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145428 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking GLASDEGIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Glasdegib https://www.ncbi.nlm.nih.gov/books/n/livertox/Glasdegib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C84862 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2043437/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads GLASDEGIB https://www.dgidb.org/drugs/GLASDEGIB IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license glasdegib https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8201 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) PF-04449913 http://idrblab.net/ttd/data/drug/details/D0S5LO ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Daurismo (EMEA/H/C/004878) https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ FDA Medication Guides https://www.fda.gov/about-fda/about-website/website-policies#linking Daurismo https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking GLASDEGIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html glasdegib https://rxnav.nlm.nih.gov/id/rxnorm/2105845 Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=28054141-990751638 Thieme Chemistry. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=28054141-990724844 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Glasdegib https://www.wikidata.org/wiki/Q27077810 PubChem https://pubchem.ncbi.nlm.nih.gov Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html glasdegib https://www.ncbi.nlm.nih.gov/mesh/2003115 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG https://www.kegg.jp/kegg/legal.html USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 391613312 https://pubchem.ncbi.nlm.nih.gov/substance/391613312 Show More